SE8501050D0 - Biologically active fragments of human antihemophilic factor and method for preparation thereof - Google Patents

Biologically active fragments of human antihemophilic factor and method for preparation thereof

Info

Publication number
SE8501050D0
SE8501050D0 SE8501050A SE8501050A SE8501050D0 SE 8501050 D0 SE8501050 D0 SE 8501050D0 SE 8501050 A SE8501050 A SE 8501050A SE 8501050 A SE8501050 A SE 8501050A SE 8501050 D0 SE8501050 D0 SE 8501050D0
Authority
SE
Sweden
Prior art keywords
preparation
biologically active
active fragments
antihemophilic factor
human antihemophilic
Prior art date
Application number
SE8501050A
Other languages
English (en)
Swedish (sv)
Inventor
L-O Andersson
N Forsman
K E I Larsen
A B Lundin
B Pavlu
I H Sandberg
K M Sewerin
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20359353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8501050(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of SE8501050D0 publication Critical patent/SE8501050D0/xx
Priority to SE8501050A priority Critical patent/SE8501050D0/xx
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to DE8686850067T priority patent/DE3680368D1/de
Priority to EP86850067A priority patent/EP0197901B1/fr
Priority to AT86850067T priority patent/ATE65505T1/de
Priority to DK085786A priority patent/DK164282B/da
Priority to JP61045506A priority patent/JPS61205219A/ja
Priority to US06/835,914 priority patent/US4749780A/en
Priority to CA000503239A priority patent/CA1341497C/fr
Priority to US07/185,629 priority patent/US4877614A/en
Priority to SG18/93A priority patent/SG1893G/en
Priority to HK152/93A priority patent/HK15293A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D31/00—Protective arrangements for foundations or foundation structures; Ground foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Structural Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Civil Engineering (AREA)
  • Paleontology (AREA)
  • Mining & Mineral Resources (AREA)
  • Hydrology & Water Resources (AREA)
  • Environmental & Geological Engineering (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE8501050A 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof SE8501050D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE8686850067T DE3680368D1 (de) 1985-03-05 1986-02-24 Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
EP86850067A EP0197901B1 (fr) 1985-03-05 1986-02-24 Fragments du facteur antihémophilique possédant une activité biologique, leur procédé de préparation et préparations pharmaceutiques
AT86850067T ATE65505T1 (de) 1985-03-05 1986-02-24 Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
DK085786A DK164282B (da) 1985-03-05 1986-02-25 Biologisk aktive fragmenter af human antihaemofilisk faktor viii:c, anvendelse af fragmenterne og fremgangsmaade til fremstilling af dem
JP61045506A JPS61205219A (ja) 1985-03-05 1986-03-04 生物学的に活性なヒト第８因子断片からなる抗血友病剤およびその製造方法
CA000503239A CA1341497C (fr) 1985-03-05 1986-03-04 Fragments du facteur antihemophilique humain ayant une activite biologique, ainsi que leur methode de preparation
US06/835,914 US4749780A (en) 1985-03-05 1986-03-04 Biologically active fragments of human antihemophilic factor and method for preparation thereof
US07/185,629 US4877614A (en) 1985-03-05 1988-04-25 Biologically active fragments of human antihemophilic factor and method for preparation thereof
SG18/93A SG1893G (en) 1985-03-05 1993-01-05 Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
HK152/93A HK15293A (en) 1985-03-05 1993-02-25 Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof

Publications (1)

Publication Number Publication Date
SE8501050D0 true SE8501050D0 (sv) 1985-03-05

Family

ID=20359353

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof

Country Status (10)

Country Link
US (2) US4749780A (fr)
EP (1) EP0197901B1 (fr)
JP (1) JPS61205219A (fr)
AT (1) ATE65505T1 (fr)
CA (1) CA1341497C (fr)
DE (1) DE3680368D1 (fr)
DK (1) DK164282B (fr)
HK (1) HK15293A (fr)
SE (1) SE8501050D0 (fr)
SG (1) SG1893G (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0251843A1 (fr) * 1986-06-06 1988-01-07 Transgene S.A. Procédé de préparation de facteur VIII à partir de cellules de mammifères
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
AU607927B2 (en) * 1986-06-24 1991-03-21 Nordisk Gentofte A/S A process for producing a coagulation active complex of factor viii fragments
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0725708B1 (fr) * 1992-04-06 1998-07-08 Pressmaster Tool Ab Outil de sertissage
WO1994007510A1 (fr) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprenant une formulation d'un facteur de coagulation viii, procede pour sa preparation et utilisation d'un agent tensioactif comme stabilisateur
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
CA2252896C (fr) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Facteur viii resistant a l'inactivation
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6143179A (en) * 1996-06-24 2000-11-07 Kerckhoff-Klinik Gmbh Method for the affinity-chromatographic purification of factor VIII
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) * 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
EP1038959A1 (fr) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Facteur VIII sans domaine B, comprenant une ou plusieurs insertions d'intron I tronqué du facteur IX
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP1233064A1 (fr) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung ADNc modifier du facteur VIII et son d'utilisation pour la production du facteur VIII
EP2110385A1 (fr) 2001-06-14 2009-10-21 The Scripps Research Institute Facteur VIII stabilisé doté de liens disulfure construits
EP1418810A4 (fr) 2001-08-03 2006-08-02 Us Gov Health & Human Serv Traitement de l'hemophilie par voie orale
CA2709890A1 (fr) 2007-12-27 2009-07-09 Andre Giovagnoli Procedes de culture de cellules
CA2834788C (fr) * 2011-05-05 2020-11-17 Coordinated Program Development, Llc Compositions de cochleate et leurs procedes de fabrication et d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
FI841281A7 (fi) * 1983-03-31 1984-10-01 Scripps Clinic And Res Foundation VIII koagulantti-polypeptidien uusi tekijä ja niiden monoklonaaliset vasta-aineet.
DE3481109D1 (de) * 1983-05-09 1990-03-01 Novo Nordisk As Antihaemophilie-faktor-viii-konzentrat und dessen herstellungsverfahren.
DE3586402T3 (de) * 1984-01-12 2004-12-23 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Proteinzusammensetzung mit Koagulations-wirkung und Verfahren zu ihrer Herstellung.
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof

Also Published As

Publication number Publication date
HK15293A (en) 1993-03-05
DK164282B (da) 1992-06-01
US4749780A (en) 1988-06-07
ATE65505T1 (de) 1991-08-15
JPH0547524B2 (fr) 1993-07-19
DK85786A (da) 1986-09-06
CA1341497C (fr) 2006-02-14
EP0197901A1 (fr) 1986-10-15
EP0197901B1 (fr) 1991-07-24
US4877614A (en) 1989-10-31
DK85786D0 (da) 1986-02-25
JPS61205219A (ja) 1986-09-11
DE3680368D1 (de) 1991-08-29
SG1893G (en) 1993-06-11

Similar Documents

Publication Publication Date Title
SG1893G (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
FI883936A7 (fi) Sokeritaudin hoito, hoidossa käyttökelpoiset valmisteet ja niiden valmistus
ATE63813T1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
DE3880766D1 (de) Konjugate von interferon alpha mit immunglobulinen.
DE3582439D1 (de) Mittel zur behandlung von herzerkrankungen.
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
DE3769707D1 (de) Therapeutisches system mit geregelter wirkstoffabgabe.
NO862096L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator.
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
IL81573A (en) Pharmaceutical preparations for the treatment of psoriasis containing tamoxifen
HU907959D0 (en) Medical preparations
DE69431046D1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
IT8548055A1 (it) Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale
FI864164A7 (fi) Ihmis- -interferonin biologisesti aktiivisia johdoksia, niiden valmistus ja tällaisia johdoksia sisältävlääkkeitä.
BG44709A3 (bg) Метод за получаване на 9-хлор-1,5-бензотиазепинови производни
TR199901385T2 (xx) Piperidin t�revleri.
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE159171T1 (de) Arzneimittelzusammensetzung enthaltend tcf-ii
ES8603270A1 (es) Procedimiento para preparar liposomas que contiene alergenoso fracciones de alergenos inhalables
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.
GR880100401A (el) 8α-ακυλαμινεργολινη,παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν.
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer